143224-63-9

Upstream product

• 143224-62-8 (2R,3S)-3-benzyloxycarbonylamino-2-hydroxy-1-(N-isobutylamino)-4-phenylbutane 
• 1609-86-5 Tert-butyl isocyanate 
• 128018-43-9 N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol 
• 26049-94-5 (S)-benzyl (4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate 
• 128018-44-0 N-benzyloxycarbonyl-3(S)-amino-1,2(S)epoxy-4-phenylbutane 

Downstream Products

• 143224-34-4 Telinavir 
• 143224-65-1 {(S)-1-[(1S,2R)-1-Benzyl-3-(3-tert-butyl-1-isobutyl-ureido)-2-hydroxy-propylcarbamoyl]-2-carbamoyl-ethyl}-carbamic acid benzyl ester 
• 143224-66-2 (S)-2-Amino-N¹-[(1S,2R)-1-benzyl-3-(3-tert-butyl-1-isobutyl-ureido)-2-hydroxy-propyl]-succinamide 

Relevant academic research and scientific papers

Self-emulsifying drug delivery system

Oral pharmaceutical formulation which improves the bioavailability of pharmaceuticals which are substantially water and oil insoluble is disclosed. In addition to the pharmaceutical, the formulation includes an emulsifier, an oil and an solubilizer. Alter

A Practical Synthesis of an HIV Protease Inhibitor Intermediate - Diastreoselective Epoxide Formation from Chiral α-Aminoaldehydes

A practical and efficient synthesis of an HIV protease inhibitor intermediate has been developed based on the diastereoselective epoxide formation from a chiral α-aminoaldehyde and an in situ generated halomethyllithium reagent.